Oncologists have characterised the genomic landscape of a rare and aggressive type of gastric cancer and identified several genes with tumour-promoting effects, paving the way for better-targeted...
Understanding the link between central precocious puberty and MKRN3 gene could provide a new avenue for managing non-small cell lung cancers. A team of researchers from the Shanghai Institute of...
An emerging class of anticancer drugs known as vascular – disrupting agents (VDAs) have been developed through preclinical and clinical trials that function to selectively target the formed blood...
Eisai, a Japanese pharmaceutical company, receives New Drug Approval for its in-house developed anticancer agent Halaven. The China National Medical Products Administration (NMPA) has approved the...
